Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.53), $0.09 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.03 million.

GUIDANCE:

Acadia Pharma sees FY2017 revenue of $124-127 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.